Brief: Imunon Reports Interim Progression-Free Survival And Overall Survival Data In Phase 1/2 Ovation 2 Study In Advanced Ovarian Cancer

Imunon

28/09/2023 13:37

Sept 28 (Reuters) - Imunon Inc  IMNN.O :
    * IMUNON REPORTS INTERIM PROGRESSION-FREE SURVIVAL AND
OVERALL
SURVIVAL DATA IN PHASE 1/2 OVATION 2 STUDY IN ADVANCED OVARIAN
CANCER
    * IMUNON INC - INTENT-TO-TREAT POPULATION SHOWS 9-MONTH OS
IMPROVEMENT OVER CONTROL ARM
    * IMUNON INC - SUBGROUP OF PATIENTS TREATED WITH IMNN-001 +
PARPI
SHOWS MEANINGFUL PFS AND OS TREND COMPARED WITH CONTROL ARM
    * IMUNON INC - CONTINUED FOLLOW-UP IS INDICATED TO CONFIRM
INITIAL
OBSERVATIONS
    * IMUNON INC - CONTINUE TO MONITOR PATIENTS ENROLLED IN
OVATION 2,
WITH EXPECTATIONS TO REPORT TOPLINE RESULTS IN MID-2024

Source text for Eikon:  ID:nGNX3cf6XJ 
Further company coverage:  IMNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))